Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 880 participants.
Also called NCT02489968
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 880 participants
- Registry
-
NCT02489968
-
- Other papers using this trial's data
- Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02489968. Randomized; double masking; primary purpose treatment. Start 2015-05-12 (actual); primary completion 2016-11-18 (actual). Results posted on 2018-09-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- empagliflozin 10 mg + linagliptin 5 mg
- Intervention (Drug)
- empagliflozin 10 mg
- Intervention (Drug)
- empagliflozin 25 mg + linagliptin 5 mg
- Intervention (Drug)
- empagliflozin 25 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02489968- Content hash
ca71ef9c1af9737946185346a5afac7db70ac5a248dfc6b09d66f0fe501e890b